[go: up one dir, main page]

CL2008000202A1 - Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. - Google Patents

Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Info

Publication number
CL2008000202A1
CL2008000202A1 CL2008000202A CL2008000202A CL2008000202A1 CL 2008000202 A1 CL2008000202 A1 CL 2008000202A1 CL 2008000202 A CL2008000202 A CL 2008000202A CL 2008000202 A CL2008000202 A CL 2008000202A CL 2008000202 A1 CL2008000202 A1 CL 2008000202A1
Authority
CL
Chile
Prior art keywords
acetamide
aryl
useful
pharmaceutical composition
pain
Prior art date
Application number
CL2008000202A
Other languages
English (en)
Inventor
Hideharu Uchida
Shinichi Ogawa
Nuneyoshi Makabe
Yoshitaka Maeda
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of CL2008000202A1 publication Critical patent/CL2008000202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de n-aril-acetamida; composición farmacéutica, útiles para prevenir o tratar el dolor.
CL2008000202A 2007-01-24 2008-01-24 Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. CL2008000202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007014372 2007-01-24

Publications (1)

Publication Number Publication Date
CL2008000202A1 true CL2008000202A1 (es) 2009-10-02

Family

ID=39644589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008000202A CL2008000202A1 (es) 2007-01-24 2008-01-24 Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Country Status (14)

Country Link
EP (1) EP2128157A4 (es)
JP (1) JPWO2008091021A1 (es)
KR (1) KR20090107068A (es)
CN (1) CN101589038A (es)
AR (1) AR065014A1 (es)
AU (1) AU2008208224A1 (es)
CA (1) CA2676020A1 (es)
CL (1) CL2008000202A1 (es)
CO (1) CO6210825A2 (es)
MX (1) MX2009007954A (es)
PA (1) PA8766901A1 (es)
PE (1) PE20081692A1 (es)
TW (1) TW200902002A (es)
WO (1) WO2008091021A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908753B1 (en) 2005-07-22 2014-12-17 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
MX2008013428A (es) * 2006-04-18 2008-11-04 Abbott Lab Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos.
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
EA201071280A1 (ru) * 2008-06-17 2012-05-30 Гленмарк Фармасьютикалс С.А. Производные хроманов как модуляторы trpv3
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
AR085530A1 (es) 2011-03-25 2013-10-09 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
AU2020335426B2 (en) * 2019-08-23 2025-08-14 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative
US12410119B2 (en) 2019-09-12 2025-09-09 BASF Agro B.V. Process for the preparation of a-methyl-[4-(nitro)-2-(trifluoromethyl)-benzyl nitrate
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309621D0 (en) 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
RU2137760C1 (ru) 1993-08-26 1999-09-20 Яманоути Фармасьютикал Ко., Лтд. Производное бензазепина, фармацевтическая композиция, производное дифторбензазепина и производное (замещенного) аминобензоилдифторбензазепина
DE19620170A1 (de) 1996-05-20 1997-11-27 Wolfgang Prof Dr Dr Pfleiderer Nucleosid-Derivate mit photolabilen Schutzgruppen
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
AU1309701A (en) 1999-11-15 2001-05-30 Nissan Chemical Industries Ltd. Hydrazone compounds and pesticides
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
RU2268882C1 (ru) 2001-11-16 2006-01-27 Яманоути Фармасьютикал Ко., ЛТД Производное 4,4-дифтор-1,2,3,4-тетрагидро-5н-бензазепина, его соль и содержащая его фармацевтическая композиция
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
EP1480954B1 (en) * 2002-02-15 2008-12-03 Glaxo Group Limited Vanilloid receptor modulators
DE60312154T2 (de) * 2002-05-29 2007-06-21 Amgen Inc., Thousand Oaks 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
US20060100245A1 (en) 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
EP1603883B1 (en) 2003-02-03 2012-03-28 Janssen Pharmaceutica NV Quinoline-derived amide modulators of vanilloid vr1 receptor
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
PT1632477T (pt) 2003-06-12 2017-04-04 Astellas Pharma Inc Derivado de benzamida ou seu sal
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
DK2017276T3 (da) 2003-09-22 2011-04-18 Euro Celtique Sa Phenylcarboxamid-forbindelser til behandling af smerte
BRPI0415179A (pt) 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1685112B1 (en) 2003-11-08 2011-07-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives as vr1 antagonists
JP2007526910A (ja) 2004-01-23 2007-09-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドとしてのビス二環式アミド類ならびに炎症性および神経因性疼痛の治療におけるそれらの使用
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
WO2006006741A1 (ja) 2004-07-15 2006-01-19 Japan Tobacco Inc. 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
WO2006038871A1 (en) 2004-10-08 2006-04-13 Astrazeneca Ab New hydroxymethylbenzothiazoles amides
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
JP2007014372A (ja) 2005-07-05 2007-01-25 Kariya Mokuzai Kogyo Kk 椅子
EP1908753B1 (en) * 2005-07-22 2014-12-17 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative

Also Published As

Publication number Publication date
TW200902002A (en) 2009-01-16
EP2128157A1 (en) 2009-12-02
CN101589038A (zh) 2009-11-25
JPWO2008091021A1 (ja) 2010-05-20
MX2009007954A (es) 2009-08-07
CO6210825A2 (es) 2010-10-20
WO2008091021A1 (ja) 2008-07-31
EP2128157A4 (en) 2010-03-17
AR065014A1 (es) 2009-05-13
CA2676020A1 (en) 2008-07-31
AU2008208224A1 (en) 2008-07-31
PA8766901A1 (es) 2009-06-23
KR20090107068A (ko) 2009-10-12
PE20081692A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
ECSP088752A (es) Formulaciones para administración parenteral de compuestos y sus usos
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ